fda 5
- Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause
- Considerations Regarding Non-Interventional Studies for Drug and Biological Products Guidance for Industry (ENG)
- Considerations Regarding Non-Interventional Studies for Drug and Biological Products Guidance for Industry
- Reflection Paper on Use of Real World Data in Non-Interventional Studies to Generate Real-World Evidence
- FDA Perspective on the Regulation of AI in Health Care and Biomedicine